Monday, October 13, 2025 7:39:35 PM
Doc Logic -
"Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work"
Maybe we will finally see @business do an article on $NWBO soon??
"A broad reevaluation of dosing has the potential to benefit hundreds of thousands of people in developing countries who otherwise wouldn’t be able to afford the drugs.
One obstacle has stood in the way: the drugmakers themselves.
Paid per dose, they stand to lose billions of dollars if doctors prescribe less medicine to their patients.
Bristol declined to assist doctors conducting trials of lower-dose Opdivo in India, doctors say there; they ended up getting the medication from other sources, such as charities.
Merck went so far as to eliminate smaller vials of Keytruda, effectively requiring hospitals to use more than might be needed.
Used to treat melanoma and many other forms of cancer, Keytruda is now the best-selling drug of any kind in the world, with $29.5 billion in sales last year...."
"Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work"
— kristen shaughnessy (@kshaughnessy2) September 25, 2025
Maybe we will finally see @business do an article on $NWBO soon??
"A broad reevaluation of dosing has the potential to benefit hundreds of thousands of people in developing countries who otherwise wouldn’t… pic.twitter.com/bDFcrlQsTy
"Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work"
Maybe we will finally see @business do an article on $NWBO soon??
"A broad reevaluation of dosing has the potential to benefit hundreds of thousands of people in developing countries who otherwise wouldn’t be able to afford the drugs.
One obstacle has stood in the way: the drugmakers themselves.
Paid per dose, they stand to lose billions of dollars if doctors prescribe less medicine to their patients.
Bristol declined to assist doctors conducting trials of lower-dose Opdivo in India, doctors say there; they ended up getting the medication from other sources, such as charities.
Merck went so far as to eliminate smaller vials of Keytruda, effectively requiring hospitals to use more than might be needed.
Used to treat melanoma and many other forms of cancer, Keytruda is now the best-selling drug of any kind in the world, with $29.5 billion in sales last year...."
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
